ZYMOSENSE INC.

Biotech · Private

Fluorescence-based enzyme activity-sensing platform with modular probes and handheld reader for rapid characterization of industrial biocatalysts

Grants
$256K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Platform for rapid assessment of hydrolytic enzyme activity to optimize their design and use$256,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2855Varigen Biosciences Corporation——
2856Kite Pharma, Inc.—$79M
2857Eyedesis Biosciences, LLC——
2858ZYMOSENSE INC.——
2859KERACEUTICALS, INC.——
2860INFLAMACORE LIMITED LIABILITY COMPANY——
2861RNACONNECT INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.